JP5357372B2 - Skin symptom improving agent - Google Patents

Skin symptom improving agent Download PDF

Info

Publication number
JP5357372B2
JP5357372B2 JP2004075607A JP2004075607A JP5357372B2 JP 5357372 B2 JP5357372 B2 JP 5357372B2 JP 2004075607 A JP2004075607 A JP 2004075607A JP 2004075607 A JP2004075607 A JP 2004075607A JP 5357372 B2 JP5357372 B2 JP 5357372B2
Authority
JP
Japan
Prior art keywords
acid
skin
caffeylquinic
ferrylquinic
improving agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004075607A
Other languages
Japanese (ja)
Other versions
JP2005263652A (en
Inventor
陽一 新井
靖 塩屋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP2004075607A priority Critical patent/JP5357372B2/en
Publication of JP2005263652A publication Critical patent/JP2005263652A/en
Application granted granted Critical
Publication of JP5357372B2 publication Critical patent/JP5357372B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

本発明は、目のくま、肌乾燥、肌色不良等の皮膚症状改善剤に関する。   The present invention relates to a skin symptom improving agent such as a bear for eyes, dry skin, and poor skin color.

目のくま、肌乾燥、肌色不良等の皮膚症状は、ストレス、寝不足、外環境の変化等によって出現し、美容上及び健康面から、女性だけでなく男性にとっても大きな悩みの一つとなっている。これらの皮膚症状の改善には、通常、睡眠、化粧料の塗布、マッサージ等が行なわれている(特許文献1〜6)。
特開平08−26967号公報 特開2002−65404号公報 特開2004−2218号公報 特開2004−2277号公報 特開2002−200020号公報 特開2001−104354号公報
Skin symptoms such as dark circles, dry skin, poor skin color, etc. appear due to stress, lack of sleep, changes in the external environment, etc., and are one of the major concerns for men as well as women from the viewpoint of beauty and health. . For improvement of these skin symptoms, sleep, cosmetic application, massage, etc. are usually performed (Patent Documents 1 to 6).
Japanese Patent Laid-Open No. 08-26967 JP 2002-65404 A JP 2004-2218 A Japanese Patent Laid-Open No. 2004-2277 Japanese Patent Laid-Open No. 2002-200020 JP 2001-104354 A

しかしながら、従来の皮膚症状改善剤は、化粧料等皮膚に塗布して本来の肌色を隠蔽するものがほとんどであり、皮膚症状そのものを改善するものではない。
従って、本発明の目的は皮膚症状自体を改善する組成物を提供することにある。
However, most conventional skin symptom improving agents are applied to the skin such as cosmetics to conceal the original skin color and do not improve the skin symptom itself.
Accordingly, an object of the present invention is to provide a composition that improves the skin symptoms themselves.

そこで本発明者は、長期的に服用又は摂取することができる安全性の高い成分の中から肌色不良等の皮膚症状改善効果を有する成分を見出すべく種々検討した結果、クロロゲン酸類、カフェ酸、フェルラ酸及びそれらの薬学的に許容される塩から選ばれる1種以上が優れた皮膚症状改善効果を有することを見出した。また、本発明の素材は、日常生活において摂取が容易であることから安全な健康食品や医薬品として有用であることを見出した。
すなわち、本発明は、クロロゲン酸類、カフェ酸、フェルラ酸及びそれらの薬学的に許容される塩から選ばれる1種以上を有効成分とする皮膚症状改善剤を提供するものである。
Therefore, as a result of various investigations to find out a component having an effect of improving skin symptoms such as poor skin color from among highly safe components that can be taken or ingested for a long period of time, the present inventor has obtained chlorogenic acids, caffeic acid, ferrule It has been found that at least one selected from acids and pharmaceutically acceptable salts thereof has an excellent skin symptom improving effect. Moreover, since the raw material of this invention was easy to take in daily life, it discovered that it was useful as a safe health food and a pharmaceutical.
That is, this invention provides the skin symptom improving agent which uses as an active ingredient 1 or more types chosen from chlorogenic acids, caffeic acid, ferulic acid, and those pharmacologically acceptable salts.

本発明の皮膚症状改善剤は、目のくま、肌乾燥、肌色不良を改善する。これらは安全性が高く、長期間経口摂取ができることから、医薬品だけでなく機能性食品、特定保健用食品等としても有用である。   The skin symptom improving agent of the present invention improves bears on the eyes, dry skin, and poor skin color. Since these are highly safe and can be taken orally for a long period of time, they are useful not only as pharmaceuticals but also as functional foods and foods for specified health use.

本発明で用いるクロロゲン酸類、カフェ酸、フェルラ酸は、これを含有する天然物、特に植物から抽出することもでき、化学合成により工業的に製造することもできる。   The chlorogenic acids, caffeic acid, and ferulic acid used in the present invention can be extracted from natural products containing them, particularly plants, and can be industrially produced by chemical synthesis.

本発明におけるクロロゲン酸類、カフェ酸、フェルラ酸には、立体異性体が存在し、本発明では、純粋な立体異性体又はそれらの混合物を用いることができる。本発明におけるクロロゲン酸類には、具体的には、3−カフェイルキナ酸、4−カフェイルキナ酸、5−カフェイルキナ酸、3,4−ジカフェイルキナ酸、3,5−ジカフェイルキナ酸、4,5−ジカフェイルキナ酸、3−フェルリルキナ酸、4−フェルリルキナ酸、5−フェルリルキナ酸及び3−フェルリル−4−カフェイルキナ酸等が含まれる(中林ら,コーヒー焙煎の化学と技術,弘学出版株式会社,p166-167)。   The chlorogenic acids, caffeic acid, and ferulic acid in the present invention have stereoisomers, and in the present invention, pure stereoisomers or a mixture thereof can be used. Specific examples of the chlorogenic acids in the present invention include 3-caffeylquinic acid, 4-caffeylquinic acid, 5-caffeylquinic acid, 3,4-dicaffeylquinic acid, 3,5-dicaffeylquinic acid, 4,5- Dicaffeylquinic acid, 3-ferrylquinic acid, 4-ferrylquinic acid, 5-ferrylquinic acid, 3-ferryl-4-caffeylquinic acid, etc. (Nakabayashi et al., Chemistry and Technology of Coffee Roasting, Kogaku Publishing Co., Ltd.) , P166-167).

クロロゲン酸類、カフェ酸、フェルラ酸は、塩にすることにより水溶性を向上させ、生理学的有効性を増大させることができる。これらの塩としては、薬学的に許容される塩であればよい。このような塩形成用の塩基物質としては、例えば、水酸化リチウム、水酸化ナトリウム、水酸化カリウム等のアルカリ金属の水酸化物;水酸化マグネシウム、水酸化カルシウム等のアルカリ土類金属の水酸化物;水酸化アンモニウム等の無機塩基、アルギニン、リジン、ヒスチジン、オルニチン等の塩基性アミノ酸;モノエタノールアミン、ジエタノールアミン、トリエタノールアミン等の有機塩基が用いられるが、特にアルカリ金属又はアルカリ土類金属の水酸化物が好ましい。本発明においては、これらの塩を調製してから、その他の成分からなる組成物中に添加したものでもよいし、クロロゲン酸類と塩形成成分とを別々に該組成物中に添加して、この中で塩を形成せしめたものでもよい。   Chlorogenic acids, caffeic acid, and ferulic acid can improve water solubility and increase physiological effectiveness by making them into salts. These salts may be pharmaceutically acceptable salts. Examples of such basic substances for salt formation include hydroxides of alkali metals such as lithium hydroxide, sodium hydroxide and potassium hydroxide; hydroxides of alkaline earth metals such as magnesium hydroxide and calcium hydroxide. Products; inorganic bases such as ammonium hydroxide, basic amino acids such as arginine, lysine, histidine, ornithine; organic bases such as monoethanolamine, diethanolamine, and triethanolamine are used, particularly alkali metals or alkaline earth metals Hydroxides are preferred. In the present invention, these salts may be prepared and then added to a composition comprising other components, or chlorogenic acids and salt-forming components may be separately added to the composition. What formed the salt in it may be used.

クロロゲン酸類、カフェ酸を含有する天然物抽出物、特に植物抽出物としては、例えば、コーヒー、キャベツ、レタス、アーチチョーク、トマト、ナス、ジャガイモ、ニンジン、リンゴ、ナシ、プラム、モモ、アプリコット、チェリー、ヒマワリ、モロヘイヤ、カンショ、南天の葉、ブルーベリー、小麦などの植物から抽出したものが好ましい。
例えば、クロロゲン酸類は、コーヒー生豆、南天の葉、リンゴ未熟果等の植物体から抽出したものが好ましい。さらにアカネ科コーヒー(Coffee arabica LINNE)の種子より、温時アスコルビン酸、クエン酸酸性水溶液又は熱水で抽出して得たものがより好ましい。
Natural product extracts containing chlorogenic acids and caffeic acid, especially plant extracts include, for example, coffee, cabbage, lettuce, arch chalk, tomato, eggplant, potato, carrot, apple, pear, plum, peach, apricot, cherry Those extracted from plants such as sunflower, morroheiya, sweet potato, southern leaves, blueberries and wheat are preferred.
For example, chlorogenic acids are preferably extracted from plants such as green coffee beans, southern leaves, and unripe apples. Furthermore, what was obtained by extracting from the seeds of coffee arabica LINNE with warm ascorbic acid, an aqueous citric acid solution or hot water is more preferable.

具体的には、生コーヒー豆抽出物としては、長谷川香料(株)「フレーバーフォールダー」、リンゴ抽出物としては、ニッカウヰスキー(株)「アップルフェノン」、ヒマワリ種抽出物としては、大日本インキ化学工業(株)「ヘリアント」などが挙げられる。   Specifically, Hasegawa Fragrance Co., Ltd. “Flavor Folder” as raw coffee bean extract, Nikka Whiskey Co., Ltd. “Applephenon” as apple extract, Dainippon Ink Chemical Co., Ltd. as sunflower seed extract Industrial Co., Ltd. “Heliant” and the like.

フェルラ酸を含有する天然物抽出物、特に植物抽出物としては、例えば、コーヒー、タマネギ、ダイコン、レモン、センキュウ、トウキ、マツ、オウレン、アギ、カンショ、トウモロコシ、大麦、小麦、コメ等が好ましく、特にコメが好ましい。本発明におけるコメとは、イネ科イネ(Oryza sativa LINNE)の種実等の生又は乾燥物を意味する。   As a natural product extract containing ferulic acid, in particular, a plant extract, for example, coffee, onion, radish, lemon, nematode, toki, pine, auren, agi, sweet potato, corn, barley, wheat, rice and the like are preferable, Rice is particularly preferable. The rice in the present invention means raw or dried products such as seeds of Oryza sativa LINNE.

植物からフェルラ酸を抽出する方法としては、例えば、コメの糠より得られた米糠油を、室温時、弱アルカリ性下で含水エタノール及びヘキサンで分配した後、含水エタノール画分に得られたフェルラ酸エステルを、加圧下、熱時、硫酸で加水分解し、精製して得る方法が挙げられる。また、細菌(Pseudomonas)を、フトモモ科チョウジノキ(Syzygium aromaticum MERRILL et PERRY)のつぼみ及び葉より水蒸気蒸留で得られた丁子油、又は丁子油から精製して得られたオイゲノールを含む培養液で培養し、その培養液を、分離、精製して得ることもできる。   As a method for extracting ferulic acid from plants, for example, rice bran oil obtained from rice bran was distributed with water-containing ethanol and hexane under weak alkalinity at room temperature, and then ferulic acid obtained in the water-containing ethanol fraction was used. Examples thereof include a method obtained by hydrolyzing and purifying an ester with sulfuric acid under pressure and under heat. In addition, bacteria (Pseudomonas) are cultured in a culture solution containing clove oil obtained by steam distillation from buds and leaves of Syzygium aromaticum MERRILL et PERRY, or eugenol obtained by purification from clove oil. The culture solution can also be obtained by separation and purification.

またフェルラ酸は化学合成、例えば、バニリンとマロン酸との縮合反応によって製造することもできる(Journal of American Chemical Society,74,5346,1952)。   Ferulic acid can also be produced by chemical synthesis, for example, a condensation reaction between vanillin and malonic acid (Journal of American Chemical Society, 74, 5346, 1952).

本発明の前記成分は2種以上を併用してもよい。これらの成分は、成人(体重60kg)1日あたり10mg〜10g、より好ましくは35mg〜5g、さらに好ましくは70mg〜1g摂取するのが皮膚症状改善効果を得る点から好ましい。   Two or more of the above components of the present invention may be used in combination. These components are preferably taken in an amount of 10 mg to 10 g, more preferably 35 mg to 5 g, still more preferably 70 mg to 1 g per day for an adult (body weight 60 kg) from the viewpoint of obtaining an effect of improving skin symptoms.

本発明でいう皮膚症状には、目のくま、肌乾燥、肌色不良、肌荒れ、むくみ、たるみ、キメのみだれ等が含まれる。これらの症状は、外観観察により評価される。
The skin symptoms referred to in the present invention, the eyes of the bear, skin drying, skin color bad, rough skin, non-Kumi, sagging, is included is it only the texture and the like. These symptoms are evaluated by appearance observation.

クロロゲン酸類、カフェ酸、フェルラ酸及びそれらの薬学的に許容される塩から選ばれる1種以上は、皮膚症状改善剤中に0.01〜80重量%、さらに0.05〜60重量%、特に0.1〜60重量%配合するのが好ましい。   One or more selected from chlorogenic acids, caffeic acid, ferulic acid and pharmaceutically acceptable salts thereof are 0.01 to 80% by weight, more preferably 0.05 to 60% by weight, especially in the skin symptom improving agent. It is preferable to mix 0.1 to 60% by weight.

本発明の皮膚症状改善剤を医薬品として用いる場合、上記有効成分に薬学的に許容される担体を添加して、経口用又は非経口用の組成物とすることができるが、経口用がより好ましい。
経口用組成物としては、錠剤、顆粒剤、細粒剤、丸剤、散剤、カプセル剤(硬カプセル剤及び軟カプセル剤を含む)、トローチ剤、チュアブル剤、サプリメント等の固形状製剤あるいは粉末状製剤等などが挙げられる。またこれらの製剤は、サプリメント等の食品として用いてもよい。
これらの製剤中の本発明の成分の含有量は、1日あたりの有効摂取量を考慮すると0.1〜80重量%、特に10〜60重量%が好ましい。
When the skin symptom improving agent of the present invention is used as a pharmaceutical product, a pharmaceutically acceptable carrier can be added to the above active ingredient to make an oral or parenteral composition, but oral use is more preferable. .
Oral compositions include solid preparations or powders such as tablets, granules, fine granules, pills, powders, capsules (including hard capsules and soft capsules), troches, chewables, and supplements. Formulation etc. are mentioned. These preparations may be used as foods such as supplements.
The content of the component of the present invention in these preparations is preferably 0.1 to 80% by weight, particularly 10 to 60% by weight in consideration of the effective intake per day.

本発明の皮膚症状改善剤を食品として用いる場合、当該食品の形態としては、前記製剤の他、有効成分の他に慣用の食品添加物を加えた飲料、醤油、牛乳、ヨーグルト、味噌等の液状又は乳状又はペースト状の食品;ゼリー、グミ等の半固形状食品;クッキー、ガム、豆腐等の形態が挙げられる。
液状、乳状又はペースト状の食品又は半固形状食品中の本発明の成分の含有量は、1日あたりの有効摂取量を考慮すると0.01〜50重量%、特に0.05〜10重量%が好ましい。
When the skin symptom-improving agent of the present invention is used as a food, the form of the food includes liquids such as beverages, soy sauce, milk, yogurt, miso, and the like, in addition to the above-mentioned preparations, and conventional food additives in addition to active ingredients Or milky or pasty foods; semi-solid foods such as jelly and gummi; cookie, gum, tofu and the like.
The content of the component of the present invention in the liquid, milky or pasty food or semi-solid food is 0.01 to 50% by weight, particularly 0.05 to 10% by weight in consideration of the effective intake per day. Is preferred.

また、非経口用組成物としては、注射剤などの静脈内投与製剤、坐剤、皮膚外用剤などが挙げられる。   Examples of the parenteral composition include intravenous preparations such as injections, suppositories, and external preparations for skin.

本発明の皮膚症状改善剤は、安全性に優れ、健常者、半健常者、病人が日常、飲食しても何ら問題なく、錠剤、顆粒剤等のサプリメントの形態や、種々の飲料の形態、各種食品の形態、特に特定保健用食品の形態で用いてもよい。   The skin symptom-improving agent of the present invention is excellent in safety, and healthy, semi-healthy, sick people can eat and drink everyday, no problem, forms of supplements such as tablets and granules, various beverage forms, You may use in the form of various foodstuffs, especially the form of food for specific health.

試験例1 皮膚症状に対する効果
i)実験材料及び方法
女性5名を対象に実施例として生コーヒー豆抽出物を配合した野菜果実飲料30mL(クロロゲン酸類として33mg含有)、比較例として生コーヒー豆抽出物無配合の野菜果実飲料30mL(クロロゲン酸類として1.7mg含有)を作り、皮膚症状の変化を評価した。
試験は午前中の症状の程度を評価した後に飲料を摂取し、午後の症状の程度を評価した。症状の程度は次の5段階で評価し改善スコアで評価した。
Test Example 1 Effects on skin symptoms i) Experimental materials and methods 30 mL of vegetable fruit drink (containing 33 mg of chlorogenic acids) mixed with raw coffee bean extract as an example for five women, and raw coffee bean extract as a comparative example An unmixed vegetable fruit drink (30 mL) (containing 1.7 mg of chlorogenic acids) was prepared, and changes in skin symptoms were evaluated.
In the test, after evaluating the degree of morning symptom, a drink was taken and the degree of symptom in the afternoon was evaluated. The degree of symptom was evaluated by the following 5 grades and evaluated by an improvement score.

評点
1 症状を感じる
2 症状をやや感じる
3 どちらとも言えない
4 症状をあまり感じない
5 症状を感じない
改善スコア=摂取後の評点−摂取前の評点
Score 1 Feeling symptoms 2 Feeling symptoms a little 3 Not being able to say 4 Not feeling symptoms 5 Not feeling symptoms Improvement score = Score after intake-Score before intake

ii)結果
表1に肌色不良、表2にくすみの結果を示した。本発明は、いずれの症状とも改善スコアが高くこれらの症状の軽減を認めた。
ii) Results Table 1 shows the skin color defect and Table 2 shows the result of dullness. In the present invention, the improvement score was high for any symptom, and reduction of these symptoms was recognized.

Figure 0005357372
Figure 0005357372

Figure 0005357372
Figure 0005357372

実施例1(軟カプセル剤)
ゼラチン 70.0(重量%)
グリセリン 22.9
パラオキシ安息香酸メチル 0.15
パラオキシ安息香酸プロピル 0.51
水 6.44
上記組成からなる軟カプセル剤皮(オバール型、重さ150mg)の中に大豆油400mgとカフェ酸50mgとフェルラ酸50mgを定法により充填し、軟カプセル剤を製造した。
Example 1 (soft capsule)
Gelatin 70.0 (wt%)
Glycerin 22.9
Methyl paraoxybenzoate 0.15
Propyl paraoxybenzoate 0.51
Water 6.44
Soft capsule skins (oval type, weight 150 mg) having the above composition were filled with 400 mg soybean oil, 50 mg caffeic acid and 50 mg ferulic acid by a conventional method to produce soft capsules.

実施例2
次に飲料としての利用例を示す。
脱脂粉乳 3.5(重量%)
ミルクカゼイン酵素分解物 3.5
フラクトース 9.0
クロロゲン酸 0.3
フェルラ酸ナトリウム 1.0
クエン酸 0.1
アスコルビン酸 0.1
香料 0.1
水 82.4
上記組成の飲料の保存安定性は高く、また、風味も良好であった。
Example 2
Next, the usage example as a drink is shown.
Nonfat dry milk 3.5 (wt%)
Milk casein enzyme degradation product 3.5
Fructose 9.0
Chlorogenic acid 0.3
Sodium ferulate 1.0
Citric acid 0.1
Ascorbic acid 0.1
Fragrance 0.1
Water 82.4
The beverage having the above composition had high storage stability and good flavor.

Claims (3)

生コーヒー豆抽出物を有効成分とし、該生コーヒー豆抽出物に含まれる、3−カフェイルキナ酸、4−カフェイルキナ酸、5−カフェイルキナ酸、3,4−ジカフェイルキナ酸、3,5−ジカフェイルキナ酸、4,5−ジカフェイルキナ酸、3−フェルリルキナ酸、4−フェルリルキナ酸、5−フェルリルキナ酸及びその薬学的に許容される塩から選ばれる1種以上を、成人1日あたり10mg〜10gを経口摂取する、午前に摂取して午後に効果が得られるような時間で、肌色不良又はくすみの皮膚症状改善するための経口液剤 3-Caffeylquinic acid, 4-caffeylquinic acid, 5-caffeylquinic acid, 3,4-dicaffeylquinic acid, 3,5-dicaffei , which comprises a raw coffee bean extract as an active ingredient and contained in the raw coffee bean extract 10 mg to 10 g per adult per day selected from one or more selected from luquinic acid, 4,5-dicaffeylquinic acid, 3-ferrylquinic acid, 4-ferrylquinic acid, 5-ferrylquinic acid and pharmaceutically acceptable salts thereof Oral solution for improving poor skin color or dull skin symptoms at a time when it is taken orally in the morning and effective in the afternoon . 肌色不良又はくすみの皮膚症状がストレス又は寝不足によるものである、請求項1記載の経口液剤。The oral liquid preparation according to claim 1, wherein the skin symptom of poor skin color or dullness is due to stress or lack of sleep. 当該経口液剤中の有効成分の配合量が0.05〜60重量%である、請求項1又は2記載の経口液剤。 The oral liquid according to claim 1 or 2 , wherein the compounding amount of the active ingredient in the oral liquid is 0.05 to 60% by weight.
JP2004075607A 2004-03-17 2004-03-17 Skin symptom improving agent Expired - Fee Related JP5357372B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2004075607A JP5357372B2 (en) 2004-03-17 2004-03-17 Skin symptom improving agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004075607A JP5357372B2 (en) 2004-03-17 2004-03-17 Skin symptom improving agent

Publications (2)

Publication Number Publication Date
JP2005263652A JP2005263652A (en) 2005-09-29
JP5357372B2 true JP5357372B2 (en) 2013-12-04

Family

ID=35088565

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004075607A Expired - Fee Related JP5357372B2 (en) 2004-03-17 2004-03-17 Skin symptom improving agent

Country Status (1)

Country Link
JP (1) JP5357372B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2685171C1 (en) * 2015-11-13 2019-04-16 АйЭйчАй КОРПОРЕЙШН Valve drive

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070107006A (en) * 2005-02-28 2007-11-06 카오카부시키가이샤 Prophylactic antistress agent
JP2007290977A (en) * 2006-04-21 2007-11-08 Kao Corp Activity improver of active oxygen scavenging enzyme
JP4713324B2 (en) * 2005-12-13 2011-06-29 ユーシーシー上島珈琲株式会社 Hyaluronidase inhibitor
WO2012013762A2 (en) * 2010-07-30 2012-02-02 Nestec S.A. Use of green coffee and probiotic for regulating skin pigmentation
JP7048249B2 (en) * 2017-10-18 2022-04-05 花王株式会社 Foot skin indigenous bacterial plexus improving agent
CN112190507A (en) * 2020-10-28 2021-01-08 广州品赫化妆品有限公司 Composition containing poria cocos extract for removing dark circles and resisting wrinkles as well as preparation method and application of composition

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704783B2 (en) * 1990-05-23 1998-01-26 長谷川香料株式会社 Prevention method of flavor deterioration of food and drink
JP3665360B2 (en) * 1994-05-02 2005-06-29 ポーラ化成工業株式会社 Active oxygen scavenger and composition containing the same
JPH0826967A (en) * 1994-07-13 1996-01-30 Ichimaru Pharcos Co Ltd Cosmetic containing chlorogenic acid or its derivative
JPH0892057A (en) * 1994-09-16 1996-04-09 Ichimaru Pharcos Co Ltd Cosmetic blended with extract of seed of coffee tree
JPH0930987A (en) * 1995-07-20 1997-02-04 Mikio Ito Preparation for treating and preventing intractable ulcer, gastritis and dermatitis
JP3855293B2 (en) * 1996-02-14 2006-12-06 長谷川香料株式会社 Antioxidant composition
JPH11323326A (en) * 1998-02-06 1999-11-26 Nagaoka Koryo Kk Active oxygen eliminating agent, skin protecting agent and discoloration inhibitor
JP4082823B2 (en) * 1999-05-06 2008-04-30 日本メナード化粧品株式会社 Phototoxicity inhibitor
JP2001322948A (en) * 2000-05-12 2001-11-20 Kose Corp Platelet-activating factor-acetylhydrolase modulator and external reparation for skin containing the same
JP3548102B2 (en) * 2000-08-07 2004-07-28 花王株式会社 Antihypertensive agent
JP2002145737A (en) * 2000-11-10 2002-05-22 Yashiro Kogyo Kk Cosmetic with formulated ancient saltwater
JP2002142673A (en) * 2000-11-17 2002-05-21 T Hasegawa Co Ltd Lipophilic antioxidant for oil and fat cooked food and method for producing the same
JP2003176225A (en) * 2001-09-28 2003-06-24 Lion Corp Composition for oral cavity and external use for skin
JP4043220B2 (en) * 2001-11-21 2008-02-06 花王株式会社 Lipolysis promoter and slimming method
JP2003192584A (en) * 2001-12-27 2003-07-09 Kao Corp Composition for preventing and improving hypertension
JP2003212774A (en) * 2002-01-22 2003-07-30 Ichimaru Pharcos Co Ltd Maillard reaction inhibitor
JP2003289827A (en) * 2002-04-02 2003-10-14 Osaka Yakuhin Kenkyusho:Kk Supplement containing japanese parsley extract
JP4213429B2 (en) * 2002-08-12 2009-01-21 株式会社ナリス化粧品 Screening method of inorganic powder composition effective for eliminating dull skin, inorganic powder composition thereof, and cosmetics using the composition
JP4012782B2 (en) * 2002-08-16 2007-11-21 財団法人山形県産業技術振興機構 Method for identifying polyphenols in plants

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2685171C1 (en) * 2015-11-13 2019-04-16 АйЭйчАй КОРПОРЕЙШН Valve drive

Also Published As

Publication number Publication date
JP2005263652A (en) 2005-09-29

Similar Documents

Publication Publication Date Title
JP4887499B2 (en) Active oxygen scavenger and moisturizer containing wild watermelon extract
JP6811948B2 (en) Glycation inhibitor
JP2011236149A (en) In-vivo antioxidant
JP6714928B2 (en) Collagenase inhibitor
JP4916103B2 (en) Cool feeling enhancer
JP5888574B1 (en) Blood flow improver
JP4119629B2 (en) Antihypertensive agent
JP5357372B2 (en) Skin symptom improving agent
JP2017141200A (en) Absorption-promoting agent of shogaol and/or gingerol
JP2003055244A (en) Agent promoting hyaluronic acid production, cosmetics, food and beverage including the hyaluronic acid production-promoting agent
JPH10265397A (en) Agent for preventing obesity
JP2003261444A (en) Hemangioendothelial function improving agent
JP7112786B2 (en) Absorption enhancer for shogaol and/or gingerol
JP5843429B2 (en) Chilling and blood flow improver
JP4906282B2 (en) Melanin production inhibitor
JP2014169241A (en) Composition giving warm feeling
JP4641090B2 (en) Antihypertensive agent
CN109310661A (en) Improving blood flow agent, queen bee paste composition and queen bee paste composition manufacturing method
JP4542765B2 (en) Enzyme inhibitor
JP2017165686A (en) Liver function improver
JP2004137287A (en) Prophylactic/therapeutic agent for hypertension
JPWO2005056031A1 (en) Lipase inhibitor
JP6838752B2 (en) Blood flow improving composition
JP7156720B2 (en) glycation inhibitor
JP2022173468A (en) Bloodstream ameliorating composition

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100712

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110926

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20111006

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20111028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130731

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130830

R151 Written notification of patent or utility model registration

Ref document number: 5357372

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R151

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees